December 2016

Newsletter-Banner

New Study Finds Dementia Rates Are Decreasing

A team at the University of Michigan found that the percentage of American seniors with dementia is decreasing. The study also found that diabetes, high blood pressure, and obesity may raise the risk of dementia. The findings published in JAMA Internal Medicine found that people with higher levels of education had the lowest chances of developing dementia. To learn more about the study, go here 

Noninvasive Visual Stimulation May Help Reduce Alzheimer’s Plaques

Researchers at the Massachusetts Institute of Technology have used LED lights flickering at a determined frequency to reduce beta amyloid plaques seen in Alzheimer’s disease in animal models. The treatment works through brain wave stimulation, which the researchers found suppressed beta amyloid production and invigorated cells that destroyed the plaques. To learn more about the research published in Nature, go here.

New Tool May Help Predict Dementia Risk in Older Adults

To further dementia prevention research, a team of researchers in Finland and Sweden developed a dementia risk index, a tool that helps assess people’s risk of dementia and indicates target areas for preventive measures. The research team hopes the index is “useful for identifying older individuals who are most at risk, and who may also benefit most from preventive interventions.” The findings were published in the Journal of Alzheimer’s Disease and can be found here.

Potential Factor in Memory Loss May Be Identified, Holds Key to Future Drug Development

In a recent study published in Neurobiology of Aging, scientists at The Scripps Research Institute (TSRI) found that decreased levels of a protein called Rheb was linked to memory loss in animal models and increased levels of the enzyme BACE1, which is often high in Alzheimer’s disease patients. The scientists are hoping to target the Rheb pathway to allow for potential treatment options for “aging or Alzheimer’s disease-associated memory deficits.” To read the study, go here.

ICYMI: ACT-AD Held Its Ninth Annual FDA/AD Allies Meeting Last Month

The ACT-AD Coalition held its Ninth Annual FDA/AD Allies Meeting on November 16 in North Bethesda, Md., to discuss the current state of Alzheimer’s disease treatment. The theme of this year’s meeting was “Starting with the End in Mind: Aligning the Science to Close Gaps in Alzheimer’s Disease Therapeutic Development. For a recap of the meeting, go here.

The 13th International Conference on Alzheimer’s and Parkinson’s Disease Registration Deadline/March 14

Save the date! AD/PD™ 2017 takes place March 29 to April 2, 2017, in Vienna, Austria. The conference brings together clinical investigators, basic scientists, established investigators, and young talents. To learn more about the conference, go here.

Save the Date for the Cognitive Aging Summit III, April 6-7

Convened by the National Institute on Aging, the Cognitive Aging Summit III “will bring together experts in a variety of research fields to discuss the most cutting-edge advances in our understanding of age-related brain and cognitive changes, with a particular focus on resilience and reserve.” For more information, please go here.